Akero Therapeutics, Inc. (NASDAQ:AKRO) CEO Andrew Cheng Sells 108,366 Shares

Akero Therapeutics, Inc. (NASDAQ:AKRO) CEO Andrew Cheng sold 108,366 shares of the firm’s stock in a transaction on Friday, November 1st. The stock was sold at an average price of $31.73, for a total value of $3,438,453.18. Following the completion of the transaction, the chief executive officer now owns 605,417 shares in the company, valued at $19,209,881.41. The trade was a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink.

Andrew Cheng also recently made the following trade(s):

• On Friday, October 18th, Andrew Cheng sold 63,539 shares of Akero Therapeutics stock. The stock was sold at an average price of $31.53, for a total value of $2,003,384.67.
• On Wednesday, October 16th, Andrew Cheng sold 24,992 shares of Akero Therapeutics stock. The stock was sold at an average price of $31.14, for a total value of $778,250.88.
• On Tuesday, September 10th, Andrew Cheng sold 1,738 shares of Akero Therapeutics stock. The stock was sold at an average price of $26.18, for a total value of $45,500.84.

Akero Therapeutics Stock Performance

Shares of AKRO stock traded down $0.50 during mid-day trading on Tuesday, reaching $31.55. 7,638 shares of the stock traded hands, compared to its average volume of 869,998. The stock’s fifty day simple moving average is $28.42 and its two-hundred day simple moving average is $24.89. The company has a debt-to-equity ratio of 0.04, a quick ratio of 24.89 and a current ratio of 24.89. Akero Therapeutics, Inc. has a 1-year low of $13.39 and a 1-year high of $37.00.

Akero Therapeutics (NASDAQ:AKRO) last issued its earnings results on Friday, August 9th. The company reported ($0.81) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.90) by $0.09. Equities analysts predict that Akero Therapeutics, Inc. will post -3.64 earnings per share for the current year.

Institutional Investors Weigh In On Akero Therapeutics

Several hedge funds and other institutional investors have recently modified their holdings of the company. Janus Henderson Group PLC increased its holdings in shares of Akero Therapeutics by 42.2% during the first quarter. Janus Henderson Group PLC now owns 6,121,970 shares of the company’s stock valued at $154,589,000 after acquiring an additional 1,815,569 shares in the last quarter. Price T Rowe Associates Inc. MD increased its holdings in shares of Akero Therapeutics by 10.5% during the first quarter. Price T Rowe Associates Inc. MD now owns 4,060,479 shares of the company’s stock valued at $102,569,000 after acquiring an additional 384,555 shares in the last quarter. Vanguard Group Inc. increased its holdings in shares of Akero Therapeutics by 19.0% during the first quarter. Vanguard Group Inc. now owns 3,669,923 shares of the company’s stock valued at $92,702,000 after acquiring an additional 584,875 shares in the last quarter. Baker BROS. Advisors LP increased its holdings in shares of Akero Therapeutics by 14.6% during the first quarter. Baker BROS. Advisors LP now owns 2,713,205 shares of the company’s stock valued at $68,536,000 after acquiring an additional 344,827 shares in the last quarter. Finally, Redmile Group LLC increased its holdings in shares of Akero Therapeutics by 67.5% during the first quarter. Redmile Group LLC now owns 1,858,702 shares of the company’s stock valued at $46,951,000 after acquiring an additional 749,226 shares in the last quarter.

Analyst Ratings Changes

Separately, HC Wainwright restated a “buy” rating and issued a $50.00 price target on shares of Akero Therapeutics in a research report on Tuesday, September 17th. One research analyst has rated the stock with a hold rating and six have assigned a buy rating to the stock. Based on data from MarketBeat, Akero Therapeutics has an average rating of “Moderate Buy” and a consensus target price of $43.20.

About Akero Therapeutics

Akero Therapeutics, Inc, together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), which is in Phase 3 clinical trials that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients.